Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA.

J Clin Oncol. 2010 Sep 1;28(25):3922-8. doi: 10.1200/JCO.2009.25.8467. Epub 2010 Aug 2.

PMID:
20679609
2.

Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.

McBride A, Butler SK.

Am J Health Syst Pharm. 2012 May 1;69(9):745-55. doi: 10.2146/ajhp110237. Review.

PMID:
22517020
3.

Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.

Scarpace SL.

Clin Ther. 2012 Jul;34(7):1467-73. doi: 10.1016/j.clinthera.2012.06.003. Epub 2012 Jun 25. Review.

PMID:
22739019
4.

Eribulin.

Perry CM.

Drugs. 2011 Jul 9;71(10):1321-31. doi: 10.2165/11207520-000000000-00000. Review.

PMID:
21770478
5.

Eribulin mesylate for the treatment of breast cancer.

Cigler T, Vahdat LT.

Expert Opin Pharmacother. 2010 Jun;11(9):1587-93. doi: 10.1517/14656566.2010.486790. Review.

PMID:
20450446
6.

Eribulin mesylate for the treatment of late-stage breast cancer.

Gourmelon C, Frenel JS, Campone M.

Expert Opin Pharmacother. 2011 Dec;12(18):2883-90. doi: 10.1517/14656566.2011.637490. Epub 2011 Nov 17. Review.

PMID:
22087618
7.

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.

Cortes J, Montero AJ, Glück S.

Cancer Treat Rev. 2012 Apr;38(2):143-51. doi: 10.1016/j.ctrv.2011.03.006. Epub 2011 May 8. Review.

PMID:
21550727
8.

Review on the clinical use of eribulin mesylate for the treatment of breast cancer.

Aseyev O, Ribeiro JM, Cardoso F.

Expert Opin Pharmacother. 2016;17(4):589-600. doi: 10.1517/14656566.2016.1146683. Epub 2016 Feb 17. Review.

PMID:
26809667
9.

Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.

Polastro L, Aftimos PG, Awada A.

Expert Rev Anticancer Ther. 2014 Jun;14(6):649-65. doi: 10.1586/14737140.2014.920693. Review.

PMID:
24852360
10.

Advances in therapy: eribulin improves survival for metastatic breast cancer.

Morris PG.

Anticancer Drugs. 2010 Nov;21(10):885-9. doi: 10.1097/CAD.0b013e32833ed62e. Review.

PMID:
20838209
11.

Eribulin: a novel cytotoxic chemotherapy agent.

Preston JN, Trivedi MV.

Ann Pharmacother. 2012 Jun;46(6):802-11. doi: 10.1345/aph.1Q636. Epub 2012 May 22. Review.

PMID:
22619477
12.

Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?

Aftimos P, Awada A.

Adv Ther. 2011 Nov;28(11):973-85. doi: 10.1007/s12325-011-0070-9. Epub 2011 Oct 19. Review.

PMID:
22020735
13.

Eribulin mesylate.

Jain S, Vahdat LT.

Clin Cancer Res. 2011 Nov 1;17(21):6615-22. doi: 10.1158/1078-0432.CCR-11-1807. Epub 2011 Aug 22. Review.

14.

Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal.

Greenhalgh J, Bagust A, Boland A, Oyee J, Trevor N, Beale S, Dundar Y, Hockenhull J, Proudlove C, O'Reilly S.

Pharmacoeconomics. 2015 Feb;33(2):137-48. doi: 10.1007/s40273-014-0214-2. Review.

PMID:
25213036
15.

Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.

Dybdal-Hargreaves NF, Risinger AL, Mooberry SL.

Clin Cancer Res. 2015 Jun 1;21(11):2445-52. doi: 10.1158/1078-0432.CCR-14-3252. Epub 2015 Apr 2. Review.

16.

Eribulin -- a review of preclinical and clinical studies.

Swami U, Chaudhary I, Ghalib MH, Goel S.

Crit Rev Oncol Hematol. 2012 Feb;81(2):163-84. doi: 10.1016/j.critrevonc.2011.03.002. Epub 2011 Apr 14. Review.

17.

Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.

Steinberg M.

Clin Ther. 2008 Sep;30(9):1590-617. doi: 10.1016/j.clinthera.2008.09.015. Review.

PMID:
18840366
18.

The place for eribulin in the treatment of metastatic breast cancer.

Gradishar WJ.

Curr Oncol Rep. 2011 Feb;13(1):11-6. doi: 10.1007/s11912-010-0145-9. Review.

PMID:
21104168
19.

Systematic review of ixabepilone for treating metastatic breast cancer.

Li J, Ren J, Sun W.

Breast Cancer. 2017 Mar;24(2):171-179. doi: 10.1007/s12282-016-0717-0. Epub 2016 Aug 4. Review.

PMID:
27491426
20.

Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane.

Saji S.

BioDrugs. 2013 Oct;27(5):469-78. doi: 10.1007/s40259-013-0038-1. Review. Erratum in: BioDrugs. 2013 Oct;27(5):541-3.

Supplemental Content

Support Center